Vosevi (SOFOSBUVIR, VELPATASVIR, and VOXILAPREVIR)
400 mg/1 / 100 mg/1 / 100 mg/1 · Film-Coated Tablet
By Gilead Sciences, Inc.
- NDC
- 61958-2401
- Route
- Oral
- Therapeutic class
- Breast Cancer Resistance Protein Inhibitors [MoA], Breast Cancer Resistance Protein Inhibitors [MoA], HCV NS3/4A Protease Inhibitors [MoA], Hepatitis C Virus NS3/4A Protease Inhibitor , Hepatitis C Virus NS5A Inhibitor , Hepatitis C Virus Nucleotide Analog NS5B Polymerase Inhibitor , Organic Anion Transporting Polypeptide 1B1 Inhibitors [MoA], Organic Anion Transporting Polypeptide 1B1 Inhibitors [MoA], Organic Anion Transporting Polypeptide 1B3 Inhibitors [MoA], Organic Anion Transporting Polypeptide 1B3 Inhibitors [MoA], Organic Anion Transporting Polypeptide 2B1 Inhibitors [MoA], P-Glycoprotein Inhibitors [MoA], P-Glycoprotein Inhibitors [MoA], RNA Replicase Inhibitors [MoA]
- Marketing category
- NDA
Additional information
Full prescribing information for this product is available on request. Submit a sourcing request and our team will share lot details, dating, and current pricing.
Request this medication
Send a request and we'll respond with availability, lot details, and pricing within 2 business hours.
Related in Oncology & Specialty
See all →Verzenio (abemaciclib)
50 mg/1 · Tablet
Eli Lilly and Company
Available to source
Verzenio (abemaciclib)
200 mg/1 · Tablet
Eli Lilly and Company
Available to source
Verzenio (abemaciclib)
100 mg/1 · Tablet
Eli Lilly and Company
Available to source
Verzenio (abemaciclib)
150 mg/1 · Tablet
Eli Lilly and Company
Available to source
